Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

A Study Comparing the Efficacy and Safety of Valdecoxib Plus Parecoxib Versus Valdecoxib Plus Placebo for the Treatment of Pain After Coronary Artery Bypass Surgery

9. oktober 2008 oppdatert av: Pfizer

A Double-Blind Multicenter Study of the Safety and Efficacy of Parecoxib Sodium/Valdecoxib and Placebo/Valdecoxib Compared to Placebo for Treatment of Post-Surgical Pain in Patients Who Have Coronary Bypass Graft Via Median Sternotomy

The purpose of this study is to evaluate the efficacy and safety of parecoxib/valdecoxib therapy and placebo/valdecoxib therapy for the treatment of pain after coronary artery bypass surgery

Studieoversikt

Studietype

Intervensjonell

Registrering (Faktiske)

1671

Fase

  • Fase 3

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiesteder

      • Buenos Aires, Argentina, 1118
        • Pfizer Investigational Site
      • Buenos Aires, Argentina, 1416
        • Pfizer Investigational Site
      • Buenos Aires, Argentina, C1405DCS
        • Pfizer Investigational Site
    • Pcia. de Buenos Aires
      • Morón, Pcia. de Buenos Aires, Argentina, 1708
        • Pfizer Investigational Site
    • Queensland
      • Auchenflower, Queensland, Australia, 4066
        • Pfizer Investigational Site
    • South Australia
      • Ashford, South Australia, Australia, 5035
        • Pfizer Investigational Site
    • Victoria
      • Clayton, Victoria, Australia, 3168
        • Pfizer Investigational Site
      • Brussel, Belgia, 1090
        • Pfizer Investigational Site
      • Bruxelles, Belgia, 1070
        • Pfizer Investigational Site
      • Edegem, Belgia, 2650
        • Pfizer Investigational Site
      • Genk, Belgia, 3600
        • Pfizer Investigational Site
      • Liege, Belgia, B-4000
        • Pfizer Investigational Site
    • Alberta
      • Edmonton, Alberta, Canada, T6G 2B7
        • Pfizer Investigational Site
    • British Columbia
      • Vancouver, British Columbia, Canada, V6Z 1Y6
        • Pfizer Investigational Site
      • Vancouver, British Columbia, Canada, V5Z 1M9
        • Pfizer Investigational Site
    • Manitoba
      • Winnipeg, Manitoba, Canada, R3A 1R9
        • Pfizer Investigational Site
    • Nova Scotia
      • Halifax, Nova Scotia, Canada, B3H 3A7
        • Pfizer Investigational Site
    • Ontario
      • Kingston, Ontario, Canada, K7L 2V7
        • Pfizer Investigational Site
      • Kingston, Ontario, Canada, K7L 5G2
        • Pfizer Investigational Site
      • London, Ontario, Canada, N6A 5A5
        • Pfizer Investigational Site
      • Toronto, Ontario, Canada, M5G 2C4
        • Pfizer Investigational Site
      • Toronto, Ontario, Canada, M4N 3M5
        • Pfizer Investigational Site
    • Quebec
      • Fleurimont, Quebec, Canada, J1H 5N4
        • Pfizer Investigational Site
      • Montreal, Quebec, Canada, H3A 1A1
        • Pfizer Investigational Site
      • Montreal, Quebec, Canada, H1T 1C8
        • Pfizer Investigational Site
    • Saskatchewan
      • Regina, Saskatchewan, Canada, S4P 0W5
        • Pfizer Investigational Site
      • Saskatoon, Saskatchewan, Canada, S7N 0W8
        • Pfizer Investigational Site
      • Bogota, Colombia
        • Pfizer Investigational Site
    • Cundinamarca
      • Bogota, Cundinamarca, Colombia, 000
        • Pfizer Investigational Site
    • Santander
      • Floridablanca, Santander, Colombia, 000
        • Pfizer Investigational Site
    • Valle
      • Cali, Valle, Colombia, Nap
        • Pfizer Investigational Site
      • Kobenhavn, Danmark, 2100
        • Pfizer Investigational Site
      • Odense C, Danmark, 5000
        • Pfizer Investigational Site
      • Moscow, Den russiske føderasjonen, 119992
        • Pfizer Investigational Site
      • Moscow, Den russiske føderasjonen, 123182
        • Pfizer Investigational Site
      • Kuopio, Finland
        • Pfizer Investigational Site
      • Kuopio, Finland, 70211
        • Pfizer Investigational Site
      • Oulu, Finland
        • Pfizer Investigational Site
      • Turku, Finland, FIN-20520
        • Pfizer Investigational Site
    • Alabama
      • Fairhope, Alabama, Forente stater, 36532
        • Pfizer Investigational Site
      • Mobile, Alabama, Forente stater, 36608
        • Pfizer Investigational Site
      • Mobile, Alabama, Forente stater, 36604
        • Pfizer Investigational Site
      • Mobile, Alabama, Forente stater, 36607
        • Pfizer Investigational Site
      • Mobile, Alabama, Forente stater, 36602
        • Pfizer Investigational Site
    • Arizona
      • Tucson, Arizona, Forente stater, 85724
        • Pfizer Investigational Site
    • Arkansas
      • Fayetteville, Arkansas, Forente stater, 72703
        • Pfizer Investigational Site
      • Springdale, Arkansas, Forente stater, 72764
        • Pfizer Investigational Site
    • California
      • Anaheim, California, Forente stater, 92801
        • Pfizer Investigational Site
      • Anaheim, California, Forente stater, 92805
        • Pfizer Investigational Site
      • Los Angeles, California, Forente stater, 90033
        • Pfizer Investigational Site
      • Los Angeles, California, Forente stater, 90095-1778
        • Pfizer Investigational Site
      • Orange, California, Forente stater, 92868
        • Pfizer Investigational Site
      • Sacramento, California, Forente stater, 95825
        • Pfizer Investigational Site
      • Sacramento, California, Forente stater, 95819
        • Pfizer Investigational Site
      • San Francisco, California, Forente stater, 94115
        • Pfizer Investigational Site
      • San Francisco, California, Forente stater, 94118-3110
        • Pfizer Investigational Site
      • San Francisco, California, Forente stater, 94143-0648
        • Pfizer Investigational Site
      • Santa Rosa, California, Forente stater, 95403
        • Pfizer Investigational Site
      • Santa Rosa, California, Forente stater, 95404
        • Pfizer Investigational Site
      • Stanford, California, Forente stater, 94305
        • Pfizer Investigational Site
    • Colorado
      • Fort Collins, Colorado, Forente stater, 80524
        • Pfizer Investigational Site
      • Fort Collins, Colorado, Forente stater, 80528
        • Pfizer Investigational Site
    • Connecticut
      • New Haven, Connecticut, Forente stater, 06520
        • Pfizer Investigational Site
      • New Haven, Connecticut, Forente stater, 06504
        • Pfizer Investigational Site
    • District of Columbia
      • Washington, District of Columbia, Forente stater, 20010
        • Pfizer Investigational Site
    • Florida
      • Brandon, Florida, Forente stater, 33511
        • Pfizer Investigational Site
      • Clearwater, Florida, Forente stater, 33756
        • Pfizer Investigational Site
      • Hudson, Florida, Forente stater, 34667
        • Pfizer Investigational Site
      • Jacksonville, Florida, Forente stater, 32216
        • Pfizer Investigational Site
      • Melbourne, Florida, Forente stater, 32901
        • Pfizer Investigational Site
      • Melbourne, Florida, Forente stater, 32901-3276
        • Pfizer Investigational Site
      • Pensacola, Florida, Forente stater, 32504
        • Pfizer Investigational Site
      • Pensacola, Florida, Forente stater, 32514
        • Pfizer Investigational Site
      • Sarasota, Florida, Forente stater, 34239
        • Pfizer Investigational Site
      • St. Petersburg, Florida, Forente stater, 33709
        • Pfizer Investigational Site
      • Tampa, Florida, Forente stater, 33613
        • Pfizer Investigational Site
    • Georgia
      • Atlanta, Georgia, Forente stater, 30322
        • Pfizer Investigational Site
      • Augusta, Georgia, Forente stater, 30901
        • Pfizer Investigational Site
    • Indiana
      • Fort Wayne, Indiana, Forente stater, 46804
        • Pfizer Investigational Site
    • Iowa
      • Iowa City, Iowa, Forente stater, 52242
        • Pfizer Investigational Site
    • Kansas
      • Kansas City, Kansas, Forente stater, 66160
        • Pfizer Investigational Site
    • Maryland
      • Baltimore, Maryland, Forente stater, 21215
        • Pfizer Investigational Site
      • Salisbury, Maryland, Forente stater, 21801
        • Pfizer Investigational Site
      • Takoma Park, Maryland, Forente stater, 20912
        • Pfizer Investigational Site
      • Towson, Maryland, Forente stater, 21204
        • Pfizer Investigational Site
    • Massachusetts
      • Boston, Massachusetts, Forente stater, 02215
        • Pfizer Investigational Site
      • Cambridge, Massachusetts, Forente stater, 02138
        • Pfizer Investigational Site
    • Michigan
      • Detroit, Michigan, Forente stater, 48202
        • Pfizer Investigational Site
      • Livonia, Michigan, Forente stater, 48150
        • Pfizer Investigational Site
      • Muskegon, Michigan, Forente stater, 49444
        • Pfizer Investigational Site
      • Royal Oak, Michigan, Forente stater, 48073
        • Pfizer Investigational Site
    • New York
      • New York, New York, Forente stater, 10029
        • Pfizer Investigational Site
      • Rochester, New York, Forente stater, 14621
        • Pfizer Investigational Site
    • Ohio
      • Cincinnati, Ohio, Forente stater, 45219
        • Pfizer Investigational Site
      • Cincinnati, Ohio, Forente stater, 45236
        • Pfizer Investigational Site
      • Dayton, Ohio, Forente stater, 45408
        • Pfizer Investigational Site
      • Dayton, Ohio, Forente stater, 45414
        • Pfizer Investigational Site
      • Sandusky, Ohio, Forente stater, 44870
        • Pfizer Investigational Site
    • Oklahoma
      • Oklahoma City, Oklahoma, Forente stater, 73112
        • Pfizer Investigational Site
      • Tulsa, Oklahoma, Forente stater, 74104
        • Pfizer Investigational Site
    • Oregon
      • Portland, Oregon, Forente stater, 97210
        • Pfizer Investigational Site
    • Pennsylvania
      • Altoona, Pennsylvania, Forente stater, 16601
        • Pfizer Investigational Site
      • Pittsburgh, Pennsylvania, Forente stater, 15212
        • Pfizer Investigational Site
      • Pittsburgh, Pennsylvania, Forente stater, 15224
        • Pfizer Investigational Site
    • South Carolina
      • Charleston, South Carolina, Forente stater, 29425
        • Pfizer Investigational Site
      • Charleston, South Carolina, Forente stater, 29406
        • Pfizer Investigational Site
      • Charleston, South Carolina, Forente stater, 29401
        • Pfizer Investigational Site
      • Charleston, South Carolina, Forente stater, 29424
        • Pfizer Investigational Site
    • Tennessee
      • Memphis, Tennessee, Forente stater, 38120
        • Pfizer Investigational Site
    • Texas
      • Amarillo, Texas, Forente stater, 79106
        • Pfizer Investigational Site
      • Fort Worth, Texas, Forente stater, 76107
        • Pfizer Investigational Site
      • Fort Worth, Texas, Forente stater, 76107-2699
        • Pfizer Investigational Site
      • Houston, Texas, Forente stater, 77030
        • Pfizer Investigational Site
      • Irving, Texas, Forente stater, 75061
        • Pfizer Investigational Site
    • Vermont
      • Burlington, Vermont, Forente stater, 05401
        • Pfizer Investigational Site
    • Virginia
      • Annandale, Virginia, Forente stater, 22003
        • Pfizer Investigational Site
      • Falls Church, Virginia, Forente stater, 22042
        • Pfizer Investigational Site
      • Fredericksburg, Virginia, Forente stater, 22401
        • Pfizer Investigational Site
      • Norfolk, Virginia, Forente stater, 23507
        • Pfizer Investigational Site
    • Washington
      • Tacoma, Washington, Forente stater, 98405
        • Pfizer Investigational Site
    • Wisconsin
      • Elkhorn, Wisconsin, Forente stater, 53121
        • Pfizer Investigational Site
      • Madison, Wisconsin, Forente stater, 53792
        • Pfizer Investigational Site
      • Milwaukee, Wisconsin, Forente stater, 53215
        • Pfizer Investigational Site
      • Dublin, Irland
        • Pfizer Investigational Site
      • Beer Sheva, Israel
        • Pfizer Investigational Site
      • Haifa, Israel
        • Pfizer Investigational Site
      • Haifa, Israel, 34362
        • Pfizer Investigational Site
      • Holon, Israel, 58100
        • Pfizer Investigational Site
      • Jerusalem, Israel, 91120
        • Pfizer Investigational Site
      • Jerusalem, Israel, 91031
        • Pfizer Investigational Site
      • Jerusalem, Israel, 91004
        • Pfizer Investigational Site
      • Petach-Tikva, Israel, 49261
        • Pfizer Investigational Site
      • Ramat-Gan, Israel
        • Pfizer Investigational Site
      • Rehovot, Israel
        • Pfizer Investigational Site
      • Tel Aviv, Israel
        • Pfizer Investigational Site
      • Tel Hashomer, Israel, 52651
        • Pfizer Investigational Site
      • Firenze, Italia, 50134
        • Pfizer Investigational Site
      • Milano, Italia, 20138
        • Pfizer Investigational Site
      • Pavia, Italia, 27100
        • Pfizer Investigational Site
      • Pisa, Italia, 56125
        • Pfizer Investigational Site
    • DF
      • Mexico City, DF, Mexico, 03100
        • Pfizer Investigational Site
      • Mexico City, DF, Mexico, 06720
        • Pfizer Investigational Site
      • Mexico City, DF, Mexico, 14050
        • Pfizer Investigational Site
    • Mexico DF
      • Mexico City, Mexico DF, Mexico, 07760
        • Pfizer Investigational Site
    • Mexico, DF
      • Mexico City, Mexico, DF, Mexico, 14000
        • Pfizer Investigational Site
      • Breda, Nederland, 4836 AE
        • Pfizer Investigational Site
      • Eindhoven, Nederland, 5623 EJ
        • Pfizer Investigational Site
      • Zwolle, Nederland, 8011 JW
        • Pfizer Investigational Site
      • Feiring, Norge, 2093
        • Pfizer Investigational Site
      • Bialystok, Polen, 15-276
        • Pfizer Investigational Site
      • Krakow, Polen, 31-202
        • Pfizer Investigational Site
      • Poznan, Polen, 61-848
        • Pfizer Investigational Site
      • Szczecin, Polen, 70-111
        • Pfizer Investigational Site
      • Warszawa, Polen, 02-097
        • Pfizer Investigational Site
      • Bucharest, Romania, 7000
        • Pfizer Investigational Site
      • Bucharest, Romania, 771181
        • Pfizer Investigational Site
      • Bucuresti, Romania, 7000
        • Pfizer Investigational Site
      • Bucuresti, Romania, 71406
        • Pfizer Investigational Site
      • Cluj-Napoca, Romania, 3400
        • Pfizer Investigational Site
      • Timisoara, Romania, 1900
        • Pfizer Investigational Site
      • Singapore, Singapore, 168752
        • Pfizer Investigational Site
      • Bratislava, Slovakia, 833 48
        • Pfizer Investigational Site
      • Kosice, Slovakia, 040-11
        • Pfizer Investigational Site
      • Barcelona, Spania, 08025
        • Pfizer Investigational Site
      • Barcelona, Spania, 08907
        • Pfizer Investigational Site
      • Madrid, Spania, 28046
        • Pfizer Investigational Site
      • Valencia, Spania, 46010
        • Pfizer Investigational Site
      • Edinburgh, Storbritannia, Eh3 9YW
        • Pfizer Investigational Site
      • Liverpool, Storbritannia
        • Pfizer Investigational Site
      • London, Storbritannia, SE1 7EH
        • Pfizer Investigational Site
      • London, Storbritannia, E2 9JX
        • Pfizer Investigational Site
      • Middlesbrough, Storbritannia, TS4 3BW
        • Pfizer Investigational Site
      • Oxford, Storbritannia, OX3 9DU
        • Pfizer Investigational Site
      • Bern, Sveits, 3010
        • Pfizer Investigational Site
      • Geneve 14, Sveits, 1211
        • Pfizer Investigational Site
      • Orebro, Sverige, SE-701 85
        • Pfizer Investigational Site
      • Stockholm, Sverige, 171 76
        • Pfizer Investigational Site
      • Uppsala, Sverige, SE 751 85
        • Pfizer Investigational Site
      • Bloemfontein, Sør-Afrika, 9300
        • Pfizer Investigational Site
      • Pretoria, Sør-Afrika, 0002
        • Pfizer Investigational Site
      • Pretoria, Sør-Afrika, 0040
        • Pfizer Investigational Site
    • Free State
      • Bloemfontein, Free State, Sør-Afrika
        • Pfizer Investigational Site
    • Gauteng
      • Pretoria, Gauteng, Sør-Afrika
        • Pfizer Investigational Site
      • Pretoria, Gauteng, Sør-Afrika, 0002
        • Pfizer Investigational Site
      • Pretoria, Gauteng, Sør-Afrika, 0084
        • Pfizer Investigational Site
    • Gauteng Province
      • Johannesburg, Gauteng Province, Sør-Afrika
        • Pfizer Investigational Site
      • Pretoria, Gauteng Province, Sør-Afrika, 0140
        • Pfizer Investigational Site
    • KwaZulu Natal
      • Durban, KwaZulu Natal, Sør-Afrika
        • Pfizer Investigational Site
    • Pretoria
      • Les Marais, Pretoria, Sør-Afrika, 0084
        • Pfizer Investigational Site
    • Western Cape
      • Parow, Western Cape, Sør-Afrika, 7500
        • Pfizer Investigational Site
      • Ceske Budejovice, Tsjekkisk Republikk, 370 87
        • Pfizer Investigational Site
      • Prague, Tsjekkisk Republikk, 100 34
        • Pfizer Investigational Site
      • Prague, Tsjekkisk Republikk, 128 00
        • Pfizer Investigational Site
      • Prague, Tsjekkisk Republikk, 14220
        • Pfizer Investigational Site
      • Prague, Tsjekkisk Republikk, 150 00
        • Pfizer Investigational Site
      • Prague 5, Tsjekkisk Republikk, 15500
        • Pfizer Investigational Site
      • Aachen, Tyskland, 52074
        • Pfizer Investigational Site
      • Bonn, Tyskland, 53105
        • Pfizer Investigational Site
      • Giessen, Tyskland, 35385
        • Pfizer Investigational Site
      • Goettingen, Tyskland, 37075
        • Pfizer Investigational Site
      • Hamburg, Tyskland, 20251
        • Pfizer Investigational Site
      • Heidelberg, Tyskland, 69120
        • Pfizer Investigational Site
      • Kassel, Tyskland, 34125
        • Pfizer Investigational Site
      • Kiel, Tyskland, 24105
        • Pfizer Investigational Site
      • Muenchen, Tyskland, 81377
        • Pfizer Investigational Site
      • Muenster, Tyskland, 48149
        • Pfizer Investigational Site
      • Graz, Østerrike, 8036
        • Pfizer Investigational Site

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

18 år til 80 år (Voksen, Eldre voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Inclusion criteria:

  • Patients expected to receive in-hospital pain medication for pain after coronary artery bypass graft surgery for at least 3 full days and pain medication over a 10-day period
  • New York Heart Association Class I to III or cardiac ejection fraction of at least 35% before surgery
  • Body mass index of less than or equal to 40 kg/m2 and weight of >55 kg
  • Patients scheduled to undergo an isolated (bypass grafting only without valve replacement, significant aortic reconstruction, or ventriculoplasty) primary CABG surgery via median sternotomy, using cardiopulmonary bypass

Exclusion criteria:

  • Patient has undergone or is going to have emergency coronary artery bypass graft surgery or surgery without cardiopulmonary bypass procedure
  • Symptomatic peripheral vascular disease
  • Heart attack within 48 hours of surgery

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Behandling
  • Tildeling: Randomisert
  • Intervensjonsmodell: Parallell tildeling
  • Masking: Dobbelt

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Eksperimentell: B
Patients received placebo matched to parecoxib sodium 40 mg IV on Day 1 following recovery from anesthesia, contingent on an acceptable postoperative status, verification of baseline eligibility, and lack of perioperative complications. A second dose of placebo matched to parecoxib sodium 20 mg IV was administered on Day 1. On the day following surgery, patients received placebo matched to parecoxib sodium 20 mg IV at 8 am and each subsequent dose was administered at 12-hour intervals. After receiving at least 6 doses of IV placebo, patients were transitioned to oral valdecoxib 20 mg taken at 12-hour intervals until the total treatment duration of 10 days had been completed.
Eksperimentell: C
Patients received placebo matched to parecoxib sodium 40 mg IV on Day 1 following recovery from anesthesia, contingent on an acceptable postoperative status, verification of baseline eligibility, and lack of perioperative complications. A second dose of placebo matched to parecoxib sodium 20 mg IV was administered on Day 1. On the day following surgery, patients received placebo matched to parecoxib sodium 20 mg IV at 8 am and each subsequent dose was administered at 12-hour intervals. After receiving at least 6 doses of IV placebo, patients were transitioned to oral placebo matched to valdecoxib 20 mg taken at 12-hour intervals until the total treatment duration of 10 days had been completed.
Placebo komparator: EN
Parecoxib sodium 40 mg intravenous (IV) on the day after surgery (Day 1) following recovery from anesthesia, contingent on an acceptable postoperative status, verification of baseline eligibility, and lack of perioperative complications. A second dose of parecoxib sodium 20 mg IV was administered on Day 1. On the day following surgery, patients received parecoxib 20 mg IV at 8 am and each subsequent dose was administered at 12-hour intervals. After receiving at least 6 doses of IV parecoxib sodium, patients were transitioned to oral valdecoxib 20 mg taken at 12-hour intervals until the total treatment duration of 10 days had been completed.

Hva måler studien?

Primære resultatmål

Resultatmål
Tidsramme
Combined incidence of the number of patients with at least 1 confirmed clinically relevant adverse event (CRAE)
Tidsramme: Day 30
Day 30

Sekundære resultatmål

Resultatmål
Tidsramme
Uønskede hendelser
Tidsramme: Dag 30
Dag 30
Livstegn
Tidsramme: Dag 30
Dag 30
Combined incidence of the number of patients with at least 1 reported CRAE and the combined incidence of the number of patients with specific reported CRAEs summarized according to the categories listed above
Tidsramme: Day 30
Day 30
Rate of supplemental analgesia consumed
Tidsramme: Days 1-10
Days 1-10
Summed Pain Intensity (SPI) of sternotomy alone and overall body pain over 8 hours (SPI 8)
Tidsramme: Day 1
Day 1
Opioid-related Symptoms Distress Scale (OR-SDS)
Tidsramme: Days 1-10
Days 1-10
Time to last Patient Controlled Analgesia (PCA) dose
Recovery measures (length of stay, intensive care unit/hospital recovery and eligibility for discharge)
Combined incidence of the number of patients with specific confirmed CRAEs in categories of cardiovascular thromboembolic CRAEs, renal CRAEs, upper gastrointestinal ulcer CRAEs, and wound healing complication CRAEs
Tidsramme: Day 30
Day 30
Serious adverse events
Tidsramme: Day 30
Day 30
Clinical laboratory assessments
Tidsramme: Day 30
Day 30
Peak Pain Intensity (PPI) of sternotomy alone and overall body pain
Tidsramme: Days 1-10
Days 1-10
Patient's and Physician's Global Evaluation of Study Medication
Tidsramme: At time of transition from intravenous to oral medication and final visit/early termination
At time of transition from intravenous to oral medication and final visit/early termination
Modified Brief Pain Inventory-short form (mBPI-sf)
Tidsramme: Days 1-10
Days 1-10
SPI of sternotomy alone and overall body pain over 12 hours (SPI 12) and 24 hours (SPI 24)
Tidsramme: Days 1-10
Days 1-10

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Sponsor

Publikasjoner og nyttige lenker

Den som er ansvarlig for å legge inn informasjon om studien leverer frivillig disse publikasjonene. Disse kan handle om alt relatert til studiet.

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart

1. januar 2003

Studiet fullført (Faktiske)

1. januar 2004

Datoer for studieregistrering

Først innsendt

7. mars 2008

Først innsendt som oppfylte QC-kriteriene

7. mars 2008

Først lagt ut (Anslag)

14. mars 2008

Oppdateringer av studieposter

Sist oppdatering lagt ut (Anslag)

10. oktober 2008

Siste oppdatering sendt inn som oppfylte QC-kriteriene

9. oktober 2008

Sist bekreftet

1. mars 2008

Mer informasjon

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere